Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mega GenomicsHKSE:06667 -0.28%71 Operating Margin % is 4.22% as of Dec. 2025, which is 83% below its 10-year median of 25.20. GuruFocus rates HKSE:06667 with a GF Score™ of 71/100 and a GF Value™ of HK$16.92 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Mega Genomics ranks better than 70.79% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Mega Genomics's Operating Income for the
six
months ended in Dec. 2025 was HK$7.7 Mil. Mega Genomics's Revenue for the
six
months ended in Dec. 2025 was HK$183.2 Mil. Therefore, Mega Genomics's Operating Margin % for the quarter that ended in Dec. 2025 was 4.22%.
Warning Sign:
Mega Genomics Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -18%.
The historical rank and industry rank for Mega Genomics's Operating Margin % or its related term are showing as below:
HKSE:06667'
s Operating Margin % Range Over the Past 10 Years
Min: 3.29 Med: 25.2 Max: 53.82
Current: 10.95
HKSE:06667's Operating Margin % is ranked better than 70.79% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.085
vs HKSE:06667: 10.95
Mega Genomics's 5-Year Average Operating Margin % Growth Rate was -18.00% per year.
Mega Genomics's Operating Income for the
six
months ended in Dec. 2025 was HK$7.7 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was HK$44.4 Mil.
Mega Genomics (HKSE:06667) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Mega Genomics Operating Margin % Related Terms
Mega Genomics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Mega Genomics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06667 vs TMO, DHR, NTRA: Operating Margin % Comparison
For the Diagnostics & Research subindustry, Mega Genomics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Genomics Operating Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Mega Genomics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Mega Genomics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mega Genomics (HKSE:06667) has a Operating Margin % of 4.22% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Mega Genomics and its competitors. This is 83% below median its historical median of 25.20. Over the past decade, Mega Genomics' Operating Margin % has ranged from 3.29 to 53.82. According to the industry distribution chart, Mega Genomics ranks #59 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 29.2%.
Is Mega Genomics' Operating Margin % too high?
Mega Genomics' current Operating Margin % of 4.22% is 83% below median its 10-year median of 25.20. Over the past 10 years, this metric has ranged from a low of 3.29 to a high of 53.82. Based on the distribution chart, Mega Genomics ranks #59 out of 202 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Mega Genomics has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mega Genomics' Operating Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Mega Genomics ranks #59 out of 202 companies for Operating Margin %. This puts Mega Genomics in the upper half of its industry. Historically, Mega Genomics' own Operating Margin % has ranged from 3.29 to 53.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Diagnostics & Research company?
A good Operating Margin % depends on the Medical Diagnostics & Research industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Mega Genomics and its competitors. Mega Genomics's current Operating Margin % is 4.22%, which is 83% below median its own 10-year median of 25.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mega Genomics stock overvalued right now?
Based on GuruFocus' analysis, Mega Genomics (HKSE:06667) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.92, compared to a current price of HK$7.08 — trading 58.2% below its estimated fair value. The current Operating Margin % is 4.22%, which is 83% below median its 10-year median of 25.20. Mega Genomics' overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Mega Genomics (HKSE:06667), the current Operating Margin % is 4.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mega Genomics (HKSE:06667) Overvalued in 2026?
Based on GuruFocus' analysis, Mega Genomics stock appears to be undervalued.
The current stock price of HK$7.08 is trading 58.2% below its estimated GF Value™ of HK$16.92.
GuruFocus considers Mega Genomics to be Possible Value Trap.
Key valuation signals for HKSE:06667:
Operating Margin %: 4.22% (83% below median its 10-year median of 25.20)
GF Value™: HK$16.92 vs. price of HK$7.08 (58.2% below fair value)
No single metric tells the full story. See the HKSE:06667 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services, ancillary services, and related products in the PRC. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening, and infectious disease diagnosis, to meet consumers' growing preventive medical needs. It generates a majority of its revenue from consumer genetic testing services.
71GF Score
Get the complete analysis for HKSE:06667
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06667 has been successfully added to your 
